NCT06629129CompletedPhase 1
Effect of Latanoprost on Optic Nerve Perfusion
Optic Nerve Head Perfusion Following Treatment with Latanoprost 0.005% in Primary Open Angle Glaucoma: an Optical Coherence Tomography Angiography Study
Source: ClinicalTrials.gov · Last updated 8 Oct 2024
Brief summary (registry, in English)
46 eyes of 23 patients have been treated with topical Latanoprost 0.005 %. visual field was performed on all eyes. NFLT was measured using OCT. Radial peripapillary capillary (RPC) vascular density was measured using OCTA . mean ocular perfusion pressure (MOPP), and RPC vascular density were measured before and after treatment BY 2-3 MONTHS
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- First submitted
- 28 Sept 2024
- Start date
- 24 Jun 2024
- Primary completion date
- 30 Aug 2024
- Lead sponsor
- Zagazig University
- Diseases
- Glaucoma
- NCT number
- NCT06629129
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 46
- From 24 Jun 2024 to the primary completion date, 30 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- optic nerve lesions other than glaucoma
Who the study is looking for
- POAG with no past ocular surgery or laser retinal treatment. No previous anti-glaucoma medications
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zagazig University Coordinator of this site? Confirm its status | Zagazig | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.